Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.85)
# 1,813
Out of 5,063 analysts
46
Total ratings
40%
Success rate
53.24%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NXTC NextCure | Upgrades: Buy | $18 | $10.51 | +71.27% | 1 | Nov 7, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $11.62 | +29.09% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $2.04 | +833.66% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $11.95 | +151.05% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.09 | +1,918.35% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $9.73 | +146.66% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $30.00 | +316.67% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $3.32 | +442.17% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $3.23 | +488.24% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $2.31 | - | 1 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $79 | $182.90 | -56.71% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $100.90 | +53.62% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $8.51 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $9.83 | +154.32% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $5.18 | +34,649.03% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $39.54 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.19 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.93 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $2.86 | +52,347.55% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.62 | +55,455.56% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $6.47 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $13.06 | +1,163.40% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $219.35 | +2.58% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $7.38 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.54 | - | 2 | Jan 4, 2017 |
NextCure
Nov 7, 2025
Upgrades: Buy
Price Target: $18
Current: $10.51
Upside: +71.27%
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $11.62
Upside: +29.09%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $2.04
Upside: +833.66%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $11.95
Upside: +151.05%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.09
Upside: +1,918.35%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $9.73
Upside: +146.66%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $30.00
Upside: +316.67%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $3.32
Upside: +442.17%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $3.23
Upside: +488.24%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.31
Upside: -
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $182.90
Upside: -56.71%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $100.90
Upside: +53.62%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $8.51
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $9.83
Upside: +154.32%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $5.18
Upside: +34,649.03%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $39.54
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.19
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $2.93
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $2.86
Upside: +52,347.55%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.62
Upside: +55,455.56%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $6.47
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $13.06
Upside: +1,163.40%
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $219.35
Upside: +2.58%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $7.38
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $1.54
Upside: -